Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

L.A. McKeown

June 07, 2023

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Todd Neale

November 10, 2018

Presentation TCT Abstracts Posters 2018

Impact of HDL to major adverse limb event in end-stage renal disease on hemodialysis due to diabetic nephropathy. from PREDICT study

Presenter: Tamon Kato

September 25, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

Impact of HDL to major adverse limb event in end-stage renal disease on hemodialysis due to diabetic nephropathy. from PREDICT study

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content